{"url_path":"/sec/dwtx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-061938-index.html","accession_number":"0001104659-26-061938","cik":"0001818844","ticker":"DWTX","issuer_name":"Dogwood Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-061938-index.html","primary_entity_key":"0001818844","primary_entity_name":"Dogwood Therapeutics, Inc."},"word_count":817,"has_tables":true,"body_markdown":"Dogwood Therapeutics, Inc._March 31, 2026\n\n0001818844--12-312026Q1000000http://fasb.org/us-gaap/2025#UsefulLifeTermOfLeaseMemberP30Mhttp://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMemberP5DP5Y6MP5Y6Mfalse0001818844dwtx:RepresentativeWarrantsMember2023-03-180001818844us-gaap:SeriesAPreferredStockMember2026-03-310001818844us-gaap:SeriesAPreferredStockMember2025-12-310001818844us-gaap:SeriesAPreferredStockMember2024-10-310001818844dwtx:SeriesaNonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2025-03-310001818844dwtx:Seriesa1NonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2025-03-310001818844dwtx:SeriesaNonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2024-12-310001818844us-gaap:AdditionalPaidInCapitalMemberdwtx:RegisteredDirectOfferingMember2025-01-012025-03-310001818844dwtx:RegisteredDirectOfferingMember2025-01-012025-03-310001818844dwtx:RegisteredDirectOfferingMember2026-01-112026-01-110001818844us-gaap:CommonStockMemberdwtx:RegisteredDirectOfferingMember2025-01-012025-03-310001818844dwtx:Seriesa1NonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-03-310001818844us-gaap:TreasuryStockCommonMember2026-03-310001818844us-gaap:RetainedEarningsMember2026-03-310001818844us-gaap:AdditionalPaidInCapitalMember2026-03-310001818844us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001818844us-gaap:TreasuryStockCommonMember2025-12-310001818844us-gaap:RetainedEarningsMember2025-12-310001818844us-gaap:AdditionalPaidInCapitalMember2025-12-310001818844us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001818844us-gaap:TreasuryStockCommonMember2025-03-310001818844us-gaap:RetainedEarningsMember2025-03-310001818844us-gaap:AdditionalPaidInCapitalMember2025-03-310001818844us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001818844us-gaap:TreasuryStockCommonMember2024-12-310001818844us-gaap:RetainedEarningsMember2024-12-310001818844us-gaap:AdditionalPaidInCapitalMember2024-12-310001818844us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001818844us-gaap:CommonStockMember2026-03-310001818844us-gaap:CommonStockMember2025-12-310001818844us-gaap:CommonStockMember2024-12-310001818844dwtx:RegisteredDirectOfferingMember2025-03-120001818844us-gaap:CommonStockMember2025-03-310001818844us-gaap:CommonStockMember2025-03-120001818844dwtx:EquityIncentivePlan2020Member2025-01-012025-12-310001818844dwtx:EquityIncentivePlan2020Member2025-12-310001818844dwtx:EquityIncentivePlan2020Member2025-01-012025-03-310001818844dwtx:EquityIncentivePlan2020Member2026-03-310001818844dwtx:SecondAmendedAndRestatedEquityIncentivePlan2020Member2026-03-310001818844dwtx:SecondAmendedAndRestatedEquityIncentivePlan2020Member2025-12-310001818844dwtx:SecondAmendedAndRestatedEquityIncentivePlan2020Member2025-11-210001818844dwtx:AmendedAndRestatedEquityIncentivePlan2020Member2025-06-180001818844dwtx:AmendedAndRestatedEquityIncentivePlan2020Member2025-06-182025-06-180001818844dwtx:AmendedAndRestatedEquityIncentivePlan2020Member2025-06-272025-06-270001818844us-gaap:ShareBasedPaymentArrangementNonemployeeMemberdwtx:SecondAmendedAndRestatedEquityIncentivePlan2020Member2025-06-182025-06-180001818844us-gaap:ShareBasedPaymentArrangementEmployeeMemberdwtx:SecondAmendedAndRestatedEquityIncentivePlan2020Member2025-06-182025-06-180001818844dwtx:SecondAmendedAndRestatedEquityIncentivePlan2020Member2025-06-182025-06-180001818844dwtx:VestingOfOptionsInTwoTranchesMemberdwtx:EquityIncentivePlan2020Memberus-gaap:ShareBasedCompensationAwardTrancheOneMember2026-01-012026-03-310001818844dwtx:NonQualifiedStockOptionsMemberdwtx:EquityIncentivePlan2020Member2026-01-012026-03-310001818844dwtx:January2026OfferingMember2026-01-012026-03-310001818844us-gaap:LeaseholdImprovementsMember2026-03-310001818844us-gaap:ComputerEquipmentMember2026-03-310001818844dwtx:OfficeEquipmentAndFurnitureMember2026-03-310001818844dwtx:OfficeEquipmentAndFurnitureMember2025-12-310001818844dwtx:LoanAgreementWithConjointIncMember2025-02-182025-02-180001818844dwtx:January2026OfferingMember2026-01-112026-01-110001818844dwtx:RegisteredDirectOfferingMember2025-03-122025-03-120001818844dwtx:SeriesA2ConvertiblePreferredStockMember2026-03-310001818844dwtx:SeriesA1ConvertiblePreferredStockMember2026-03-310001818844dwtx:PreferredStockExcludingSeriesaAndSeriesa1NonVotingConvertiblePreferredStockMember2026-03-310001818844dwtx:SeriesA2ConvertiblePreferredStockMember2025-12-310001818844dwtx:SeriesA1ConvertiblePreferredStockMember2025-12-310001818844dwtx:PreferredStockExcludingSeriesaAndSeriesa1NonVotingConvertiblePreferredStockMember2025-12-310001818844dwtx:SeriesA2ConvertiblePreferredStockMember2025-09-300001818844dwtx:SeriesA1ConvertiblePreferredStockMember2025-03-3100018188442024-10-310001818844dwtx:SeriesaNonVotingConvertiblePreferredStockMember2026-03-310001818844dwtx:Seriesa2NonVotingConvertiblePreferredStockMember2026-03-310001818844dwtx:Seriesa1NonVotingConvertiblePreferredStockMember2026-03-310001818844dwtx:PreferredStockExcludingSeriesaSeriesa1AndSeriesa2NonVotingConvertiblePreferredStockMember2026-03-310001818844dwtx:SeriesaNonVotingConvertiblePreferredStockMember2025-12-310001818844dwtx:Seriesa2NonVotingConvertiblePreferredStockMember2025-12-310001818844dwtx:Seriesa1NonVotingConvertiblePreferredStockMember2025-12-310001818844dwtx:PreferredStockExcludingSeriesaSeriesa1AndSeriesa2NonVotingConvertiblePreferredStockMember2025-12-3100018188442023-12-310001818844us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001818844us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001818844stpr:GAus-gaap:StateAndLocalJurisdictionMember2025-12-310001818844stpr:FLus-gaap:StateAndLocalJurisdictionMember2025-12-310001818844country:HKus-gaap:ForeignCountryMember2025-12-310001818844country:CAus-gaap:ForeignCountryMember2025-12-310001818844us-gaap:DomesticCountryMember2025-12-310001818844dwtx:GendreauConsultingLlcMemberus-gaap:RelatedPartyMember2026-01-012026-03-310001818844dwtx:GendreauConsultingLlcMemberus-gaap:RelatedPartyMember2025-01-012025-03-310001818844us-gaap:RetainedEarningsMember2026-01-012026-03-310001818844us-gaap:RetainedEarningsMember2025-01-012025-03-310001818844dwtx:PharmagesicHoldingsInc.Memberdwtx:HalneuronChemotherapyInducedNeuropathicPainInProcessResearchAndDevelopmentMember2026-01-012026-03-310001818844dwtx:PharmagesicHoldingsInc.Memberdwtx:HalneuronCancerRelatedPainInProcessResearchAndDevelopmentMember2026-01-012026-03-310001818844dwtx:PharmagesicHoldingsInc.Memberdwtx:HalneuronChemotherapyInducedNeuropathicPainInProcessResearchAndDevelopmentMember2024-10-082025-12-310001818844dwtx:PharmagesicHoldingsInc.Memberdwtx:HalneuronCancerRelatedPainInProcessResearchAndDevelopmentMember2024-10-082025-12-310001818844dwtx:PharmagesicHoldingsInc.Memberdwtx:HalneuronChemotherapyInducedNeuropathicPainInProcessResearchAndDevelopmentMember2026-03-310001818844dwtx:PharmagesicHoldingsInc.Memberdwtx:HalneuronCancerRelatedPainInProcessResearchAndDevelopmentMember2026-03-310001818844dwtx:PharmagesicHoldingsInc.Memberdwtx:HalneuronChemotherapyInducedNeuropathicPainInProcessResearchAndDevelopmentMember2025-12-310001818844dwtx:PharmagesicHoldingsInc.Memberdwtx:HalneuronCancerRelatedPainInProcessResearchAndDevelopmentMember2025-12-310001818844dwtx:PharmagesicHoldingsInc.Memberdwtx:HalneuronChemotherapyInducedNeuropathicPainInProcessResearchAndDevelopmentMember2024-10-070001818844dwtx:PharmagesicHoldingsInc.Memberdwtx:HalneuronCancerRelatedPainInProcessResearchAndDevelopmentMember2024-10-0700018188442025-01-012025-12-310001818844dwtx:PharmagesicHoldingsInc.Member2026-01-012026-03-310001818844dwtx:PharmagesicHoldingsInc.Member2024-10-082025-12-310001818844dwtx:PharmagesicHoldingsInc.Member2026-03-310001818844dwtx:PharmagesicHoldingsInc.Member2025-12-310001818844us-gaap:EmployeeStockOptionMemberdwtx:EquityIncentivePlan2020Member2026-03-310001818844dwtx:NonQualifiedStockOptionsMemberdwtx:EquityIncentivePlan2020Member2026-03-310001818844us-gaap:WarrantMember2026-03-3100018188442026-01-090001818844dwtx:LoanAgreementWithConjointIncMember2024-10-070001818844dwtx:SeriesA1ConvertiblePreferredStockMember2025-03-122025-03-120001818844dwtx:SeriesA1ConvertiblePreferredStockMember2025-03-120001818844us-gaap:SeriesAPreferredStockMember2025-11-212025-11-210001818844dwtx:SeriesA2ConvertiblePreferredStockMember2025-11-212025-11-210001818844dwtx:SeriesA1ConvertiblePreferredStockMember2025-11-212025-11-210001818844dwtx:SeriesaNonVotingConvertiblePreferredStockMember2025-09-290001818844dwtx:Seriesa2NonVotingConvertiblePreferredStockMember2025-09-290001818844dwtx:Seriesa1NonVotingConvertiblePreferredStockMember2025-09-2900018188442020-12-160001818844dwtx:RepresentativeWarrantsMemberdwtx:RepresentativeWarrantsMember2026-03-310001818844dwtx:CommonStockWarrantsMemberus-gaap:PrivatePlacementMember2026-03-110001818844dwtx:CommonStockWarrantsMember2026-03-110001818844dwtx:CommonStockWarrantsMember2026-01-150001818844srt:MaximumMemberdwtx:PreFundedWarrantsMemberdwtx:January2026OfferingMember2026-01-110001818844srt:MaximumMemberdwtx:CommonStockWarrantsMemberdwtx:January2026OfferingMember2026-01-110001818844dwtx:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember2026-01-110001818844dwtx:CommonStockWarrantsMemberus-gaap:PrivatePlacementMember2026-01-110001818844dwtx:PreFundedWarrantsMember2026-03-310001818844dwtx:PreFundedWarrantsMember2026-01-150001818844dwtx:RepresentativeWarrantsMember2022-09-300001818844dwtx:UnderwriterWarrantsMember2021-12-2100018188442025-03-3100018188442024-12-310001818844dwtx:PharmagesicHoldingsInc.Member2024-10-070001818844dwtx:PharmagesicHoldingsInc.Memberus-gaap:SeriesAPreferredStockMember2024-10-072024-10-070001818844dwtx:PharmagesicHoldingsInc.Memberus-gaap:CommonClassAMember2024-10-072024-10-070001818844dwtx:LicenseAgreementForSp16DevelopmentMemberus-gaap:CommonStockMemberdwtx:SerpinLicenseAgreementMember2026-01-012026-03-310001818844dwtx:LicenseAgreementForSp16DevelopmentMemberdwtx:Seriesa2NonVotingConvertiblePreferredStockMemberdwtx:SerpinLicenseAgreementMember2026-01-012026-03-310001818844dwtx:LicenseAgreementForSp16DevelopmentMemberdwtx:SerpinLicenseAgreementMember2026-01-012026-03-310001818844us-gaap:WarrantMember2026-01-012026-03-310001818844us-gaap:PreferredStockMember2026-01-012026-03-310001818844us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001818844us-gaap:WarrantMember2025-01-012025-03-310001818844us-gaap:PreferredStockMember2025-01-012025-03-310001818844us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001818844dwtx:LoanAgreementWithConjointIncMember2026-01-012026-03-310001818844dwtx:LoanAgreementWithConjointIncMember2025-01-012025-03-310001818844us-gaap:EmployeeStockOptionMemberdwtx:EquityIncentivePlan2020Member2026-01-012026-03-310001818844us-gaap:EmployeeStockOptionMemberdwtx:EquityIncentivePlan2020Member2025-01-012025-03-310001818844us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001818844us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001818844dwtx:GendreauConsultingLlcMemberus-gaap:RelatedPartyMember2026-03-310001818844dwtx:GendreauConsultingLlcMemberus-gaap:RelatedPartyMember2025-12-310001818844dwtx:CommonStockWarrantsMemberus-gaap:PrivatePlacementMember2026-01-112026-01-110001818844dwtx:RepresentativeWarrantsMember2023-03-182023-03-180001818844dwtx:UnderwriterWarrantsMember2021-12-212021-12-210001818844srt:MinimumMember2026-03-310001818844srt:MaximumMember2026-03-310001818844dwtx:SeriesaNonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-03-310001818844us-gaap:CommonStockMember2026-01-012026-03-310001818844dwtx:EquityIncentivePlan2020Member2026-01-012026-03-310001818844srt:MinimumMemberdwtx:EquityIncentivePlan2020Member2026-01-012026-03-310001818844srt:MaximumMemberdwtx:EquityIncentivePlan2020Member2026-01-012026-03-310001818844dwtx:AtMarketOfferingMember2025-11-280001818844dwtx:SingleReportableSegmentMember2026-01-012026-03-310001818844dwtx:SingleReportableSegmentMember2025-01-012025-03-3100018188442025-09-012025-09-300001818844country:CAus-gaap:ForeignCountryMember2025-01-012025-12-310001818844us-gaap:StateAndLocalJurisdictionMember2025-01-012025-12-3100018188442026-02-280001818844dwtx:CommonStockWarrantsMember2026-01-110001818844dwtx:VestingOfOptionsInTwoTranchesMemberdwtx:EquityIncentivePlan2020Memberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2026-01-012026-03-3100018188442026-01-150001818844us-gaap:SubsequentEventMember2026-04-300001818844us-gaap:SubsequentEventMember2026-04-2100018188442026-02-012026-02-280001818844dwtx:LoanAgreementWithConjointIncMember2024-10-072024-10-070001818844us-gaap:CommonStockMember2025-03-122025-03-120001818844dwtx:PharmagesicHoldingsInc.Member2024-10-172024-10-170001818844dwtx:KnowHowLicenseAgreementMember2012-01-012012-12-310001818844dwtx:UnderwriterWarrantsMember2025-01-012025-12-310001818844dwtx:UnderwriterWarrantsMember2025-12-310001818844dwtx:January2026OfferingMember2026-01-110001818844dwtx:PreFundedWarrantsMemberus-gaap:SubsequentEventMember2026-04-012026-04-010001818844dwtx:PreFundedWarrantsMember2026-01-012026-03-3100018188442025-01-012025-03-310001818844dwtx:UnderwriterWarrantsMember2026-01-012026-03-310001818844dwtx:PharmagesicHoldingsInc.Member2024-10-072024-10-070001818844dwtx:UnderwriterWarrantsMember2026-03-310001818844dwtx:CommonStockWarrantsMember2026-03-310001818844dwtx:CommonStockWarrantsMemberdwtx:January2026OfferingMember2026-01-1100018188442026-03-3100018188442025-12-3100018188442026-05-1300018188442026-01-012026-03-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:puredwtx:leasedwtx:Miso4217:CADutr:sqftutr:sqftdwtx:segment\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n​\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**FORM ****10-Q**\n\n​\n\n​\n\n**(Mark One)**\n\n​\n\n**☒**\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n​\n\n**For the quarterly period ended****March 31, 2026**\n\n​\n\n**or**\n\n​\n\n​\n\n​\n\n**☐**\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n​\n\n**For the transition period from****                   ****  to****                   **** **\n\n​\n\n**Commission File Number:****001-39811**\n\n**Dogwood Therapeutics, Inc.**\n\n**(Exact name of registrant as specified in its charter)**\n\n​\n\n​\n\n​\n\n**Delaware**\n\n85-4314201\n\n**(State or other jurisdiction of**\n\n**incorporation or organization)**\n\n**(I.R.S. Employer**\n\n**Identification Number)**\n\n​\n\n**44 Milton Avenue**\n\n**Alpharetta****,****GA********30009**\n\n**(Address of Principal Executive Offices)**\n\n**(****866****)****620-8655**\n\n**(Registrant’s telephone number)**\n\n**Not applicable**\n\n**(Former name, former address and former fiscal year, if changed since last report)**\n\n​\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\n**Title of Each Class**\n\n**Trading symbol**\n\n**Name of Exchange on which registered**\n\n**Common Stock, par value $0.0001 per share**\n\n**DWTX**\n\n**Nasdaq****Capital Market**\n\n​\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  ⌧    No  ◻\n\n​\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  ⌧    No   ◻\n\n​\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nLarge accelerated filer\n\n◻\n\nAccelerated filer\n\n◻\n\n​\n\n​\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\nEmerging growth company\n\n☐\n\n​\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻\n\n​\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  ☐    No  ⌧\n\n​\n\nAs of May 13, 2026, there were 33,629,553 shares of the registrant’s common stock outstanding.\n\n​\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\n**TABLE OF CONTE****NTS**\n\n​\n\n​\n\n  ​ ​ ​\n\n​\n\n  ​ ​ ​\n\n**Page**\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[**Part I**](#PARTIFINANCIALINFORMATION_331859)\n\n​\n\n[**Financial Information**](#PARTIFINANCIALINFORMATION_331859)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 1.](#Item1FinancialStatements_784200)\n\n​\n\n[Condensed Consolidated Financial Statements](#Item1FinancialStatements_784200)\n\n​\n\n3\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 2025](#CondensedConsolidatedBalanceSheets_94173)\n\n​\n\n3\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2026 and 2025 (Unaudited)](#CondensedConsolidatedStatementsofOperati)\n\n​\n\n4\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Condensed Consolidated Statements of Changes in Series A Non-Voting Convertible Preferred Stock and Stockholders’ Equity for the three months ended March 31, 2026 and 2025 (Unaudited)](#CondensedConsolidatedStatementsofShareho)\n\n​\n\n5\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025 (Unaudited)](#CondensedConsolidatedStatementsofCashFlo)\n\n​\n\n6\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Notes to Condensed Consolidated Financial Statements (Unaudited)](#NotestoCondensedConsolidatedFinancialSta)\n\n​\n\n7\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 2.](#Item2ManagementsDiscussionandAnalysisofF)\n\n​\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF)\n\n​\n\n30\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 3.](#Item3QuantitativeandQualitativeDisclosur)\n\n​\n\n[Quantitative and Qualitative Disclosures about Market Risk](#Item3QuantitativeandQualitativeDisclosur)\n\n​\n\n37\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 4.](#Item4ControlsandProcedures_389621)\n\n​\n\n[Controls and Procedures](#Item4ControlsandProcedures_389621)\n\n​\n\n37\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[**Part II**](#PARTIIOTHERINFORMATION_542084)\n\n​\n\n[**Other Information**](#PARTIIOTHERINFORMATION_542084)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 1.](#Item1LegalProceedings_494134)\n\n​\n\n[Legal Proceedings](#Item1LegalProceedings_494134)\n\n​\n\n38\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 1A.](#Item1ARiskFactors_783247)\n\n​\n\n[Risk Factors](#Item1ARiskFactors_783247)\n\n​\n\n38\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 2.](#Item2UnregisteredSalesofEquitySecurities)\n\n​\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSalesofEquitySecurities)\n\n​\n\n38\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 3.](#Item3DefaultsUponSeniorSecurities_469674)\n\n​\n\n[Defaults Upon Senior Securities](#Item3DefaultsUponSeniorSecurities_469674)\n\n​\n\n38\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 4.](#Item4MineSafetyDisclosures_534089)\n\n​\n\n[Mine Safety Disclosures](#Item4MineSafetyDisclosures_534089)\n\n​\n\n38\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 5.](#Item5OtherInformation_510918)\n\n​\n\n[Other Information](#Item5OtherInformation_510918)\n\n​\n\n38\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Item 6.](#Item6Exhibits_448808)\n\n​\n\n[Exhibits](#Item6Exhibits_448808)\n\n​\n\n38\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Exhibit Index](#EXHIBITINDEX_736607)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n[Signatures](#SIGNATURES_449184)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n2\n\n[Table of Contents](#TOC)\n\nPART I —FINANCIAL INFORMATION"}